NCT01037205View on ClinicalTrials.gov

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

PHASE2CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Influenza
Interventions
DRUG

DAS181 dry powder, formulation F02

10 mg delivered dose DAS181 in clear HPMC #3 Capsules

DRUG

Respitose ML006 (DMV-Fonterra)

Lactose monohydrate

Trial Locations (42)

Unknown

Carmichael

Chula Vista

La Mesa

Lincoln

Los Angeles

Orange

Colorado Springs

Denver

Hialeah

Miami

Orlando

Tampa

Atlanta

Boise

Covington

Silver Spring

North Dartmouth

Bellevue

Henderson

Las Vegas

Stony Brook

Canton

Dayton

Franklin

Groveport

Miamisburg

Oklahoma City

Tulsa

Ashland

Lansdale

Pittsburgh

Myrtle Beach

Simpsonville

Rapid City

Johnson City

Austin

Georgetown

San Antonio

Salt Lake City

West Point

West Valley City

Richmond

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Ansun Biopharma, Inc.

INDUSTRY